Company honored in its commitment to patients and families living with mitochondrial disease; invites the community to walk with BPGbio colleagues and MitoAction
BOSTON, MA — September 12, 2025 — BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its sponsorship of the MitoAction Energy Walk at Boston’s Franklin Park Zoo on Saturday, September 27, 2025. The family-friendly event brings together patients, caregivers, clinicians, advocates, and supporters to raise awareness of mitochondrial diseases and to fund programs that improve quality of life for those affected.
“As a company committed to advancing mitochondrial medicine, we’re honored to support MitoAction and the patient community,” said Niven R. Narain, Ph.D., President & CEO of BPGbio. “Mitochondria are the cell’s engines, and energy failure is a common denominator across many serious, multi-system diseases such as Primary CoQ10 Deficiency (PCQD) that BPGbio is working on a treatment for. We’re grateful to organizations like MitoAction for rallying the community and raising awareness through events like the Energy Walk.”
BPGbio has a longstanding commitment to mitochondrial biology in human disease. The company has built an international research ecosystem spanning industry partners, patient advocacy groups, and academic collaborators to uncover the biological drivers of mitochondrial disorders and translate those insights into potential therapies. As the first company in the world to apply AI and systems medicine to develop treatments, BPGbio is advancing BPM31510, an investigational therapy designed to target directly to the mitochondria and is planning on a phase 3 trial for Primary CoQ10 Deficiency.
“Partnerships like this are essential to move mitochondrial medicine forward,” said Kira Mann, CEO of MitoAction. “By uniting patients, families, clinicians, and industry leaders at the Energy Walk, we build awareness today while helping catalyze better solutions for tomorrow. We appreciate BPGbio’s commitment to developing a treatment for the Primary CoQ10 Deficiency patients and the broader mitochondrial patients’ community.”
